Sign In
Buy RLAY
$15.30
-0.400 (-2.55%)
At Close: Jun 03, 2026
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-tre
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY
05:03am, Tuesday, 07'th Apr 2026
JPMorgan Chase and Co. cut its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 89.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
10:15am, Monday, 06'th Apr 2026
Relay Therapeutics (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near te
SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY
05:01am, Monday, 06'th Apr 2026
SG Americas Securities LLC increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 591.7% during the fourth quarter, according to the company in its most recent disclosure with
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
02:38am, Monday, 06'th Apr 2026
Shares of Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat repo
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
03:03pm, Thursday, 19'th Mar 2026
Nextech Invest increased its stake in Relay Therapeutics by 855,097 shares; the estimated trade value was ~$6.1 million based on average quarterly pricing. Quarter-end position value rose by $19.7 mil
The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breas
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week High on Analyst Upgrade
01:13am, Saturday, 14'th Mar 2026
Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) shares hit a new 52-week high during mid-day trading on Friday after Guggenheim raised their price target on the stock from $15.00 to $22.00.
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
12:42pm, Wednesday, 11'th Mar 2026
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
10:06am, Wednesday, 11'th Mar 2026
Relay Therapeutics (RLAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03:45pm, Friday, 06'th Mar 2026
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst
05:42am, Thursday, 05'th Mar 2026
Relay Therapeutics is approaching a pivotal clinical catalyst with the March 16th zovegalisib Phase 1/2 data readout at ESMO TAT. RLAY's financials show improved operational efficiency, with reduced R
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month High After Better-Than-Expected Earnings
02:48am, Saturday, 28'th Feb 2026
Shares of Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) hit a new 52-week high on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $1
